WASHINGTON Feb 25 The U.S. Food and Drug
Administration said on Monday it has approved Bayer AG's
drug Stivarga for the treatment of a rare type of
gastrointestinal tract cancer.
Stivarga is already approved to treat colon cancer that has
progressed after prior treatment or that has spread to other
parts of the body. Bayer will now also be able to market the
drug as a treatment for gastrointestinal stromal tumors (GIST).
Stivarga, known chemically as regorafenib, was tested in 199
patients with GIST that could not be surgically removed and had
progressed after treatment with other therapies. Patients taking
Stivarga had a delay in tumor growth progression that was on
average 3.9 months later than patients given a placebo.